Suppr超能文献

肿瘤微环境中的嗜酸性粒细胞与淋巴细胞相互作用及癌症免疫治疗。

Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

机构信息

Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Division of Allergy/Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA.

出版信息

Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.

Abstract

Eosinophils are important effector cells and therapeutic targets in allergic diseases. Emerging data indicate that eosinophils infiltrate a variety of solid tumor types and have pleiotropic activities by at least two non-mutually exclusive mechanisms: direct interactions with tumor cells, and intricate cross-talk with lymphocytes. In light of the immune checkpoint inhibition revolution in cancer therapy, we review eosinophil-lymphocyte interactions in the tumor microenvironment. We also analyze potential interactions between eosinophils and lymphocyte subsets, including T cells, natural killer cells and innate lymphoid cells. We provide perspectives on the consequences of these interactions and how eosinophils are accessory cells that can affect the response to various forms of T cell-mediated immunotherapies and might be therapeutically targeted to improve cancer immunotherapy.

摘要

嗜酸性粒细胞是过敏疾病中重要的效应细胞和治疗靶点。新出现的数据表明,嗜酸性粒细胞浸润多种实体肿瘤类型,并通过至少两种非相互排斥的机制发挥多效性作用:与肿瘤细胞的直接相互作用,以及与淋巴细胞的复杂串扰。鉴于癌症治疗中的免疫检查点抑制革命,我们回顾了肿瘤微环境中的嗜酸性粒细胞-淋巴细胞相互作用。我们还分析了嗜酸性粒细胞与淋巴细胞亚群(包括 T 细胞、自然杀伤细胞和先天淋巴细胞)之间潜在的相互作用。我们提供了对这些相互作用后果的看法,以及嗜酸性粒细胞如何作为辅助细胞影响对各种形式的 T 细胞介导的免疫疗法的反应,并可能作为治疗靶点来改善癌症免疫疗法。

相似文献

1
Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.
Nat Immunol. 2022 Sep;23(9):1309-1316. doi: 10.1038/s41590-022-01291-2. Epub 2022 Aug 24.
2
Eosinophils in the tumor microenvironment: implications for cancer immunotherapy.
J Transl Med. 2023 Aug 16;21(1):551. doi: 10.1186/s12967-023-04418-7.
3
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
Signal Transduct Target Ther. 2020 Oct 29;5(1):250. doi: 10.1038/s41392-020-00348-8.
4
Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight.
Front Immunol. 2020 Nov 30;11:571593. doi: 10.3389/fimmu.2020.571593. eCollection 2020.
5
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Front Immunol. 2021 Apr 28;12:679117. doi: 10.3389/fimmu.2021.679117. eCollection 2021.
6
Exploiting innate immunity for cancer immunotherapy.
Mol Cancer. 2023 Nov 27;22(1):187. doi: 10.1186/s12943-023-01885-w.
7
Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Front Immunol. 2021 Apr 19;12:633685. doi: 10.3389/fimmu.2021.633685. eCollection 2021.
9
Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells.
Semin Immunol. 2022 Nov;61-64:101660. doi: 10.1016/j.smim.2022.101660. Epub 2022 Oct 27.
10
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Front Immunol. 2020 Jun 23;11:1295. doi: 10.3389/fimmu.2020.01295. eCollection 2020.

引用本文的文献

1
Targeting the Exon2 splice cis-element in PD-1 and its effects on lymphocyte function.
PLoS One. 2025 Sep 8;20(9):e0331468. doi: 10.1371/journal.pone.0331468. eCollection 2025.
2
Exploring the pathogenesis of acute lung injury and its treatment through Traditional Chinese Medicine: a state-of-the-art review.
Front Pharmacol. 2025 Jul 31;16:1592458. doi: 10.3389/fphar.2025.1592458. eCollection 2025.
4
Myeloid cells in chronic liver inflammation.
Cell Mol Immunol. 2025 Jul 28. doi: 10.1038/s41423-025-01324-4.
5
Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19.
Front Med (Lausanne). 2025 Jul 9;12:1583843. doi: 10.3389/fmed.2025.1583843. eCollection 2025.
6
Environmental interpretation of the impact of vehicle emissions on prostate cancer progression.
Cancer Cell Int. 2025 Jul 18;25(1):270. doi: 10.1186/s12935-025-03906-8.
9
Peripheral eosinophils and immunotherapy response in patients with recurrent or metastatic HNSCC.
Sci Rep. 2025 May 19;15(1):17351. doi: 10.1038/s41598-025-01457-6.
10
Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma.
Cancer Biol Med. 2025 May 6;22(5):481-7. doi: 10.20892/j.issn.2095-3941.2024.0448.

本文引用的文献

1
Innate lymphoid cells and cancer.
Nat Immunol. 2022 Mar;23(3):371-379. doi: 10.1038/s41590-022-01127-z. Epub 2022 Feb 28.
5
Transcriptional Profiling of Mouse Eosinophils Identifies Distinct Gene Signatures Following Cellular Activation.
Front Immunol. 2021 Dec 14;12:802839. doi: 10.3389/fimmu.2021.802839. eCollection 2021.
6
Cytotoxic CD4 T cells in cancer: Expanding the immune effector toolbox.
Immunity. 2021 Dec 14;54(12):2701-2711. doi: 10.1016/j.immuni.2021.11.015.
8
Environmental allergens trigger type 2 inflammation through ripoptosome activation.
Nat Immunol. 2021 Oct;22(10):1316-1326. doi: 10.1038/s41590-021-01011-2. Epub 2021 Sep 16.
9
Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity.
Cancer Res. 2021 Nov 1;81(21):5555-5571. doi: 10.1158/0008-5472.CAN-21-0839. Epub 2021 Aug 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验